{"id":561,"date":"2022-05-19T15:00:21","date_gmt":"2022-05-19T15:00:21","guid":{"rendered":"https:\/\/medicalmarijuanainc.com\/?p=1013653"},"modified":"2022-05-19T15:00:21","modified_gmt":"2022-05-19T15:00:21","slug":"medical-marijuana-inc-reports-7-8-million-in-net-revenue-in-2022-first-quarter-financial-and-operational-results","status":"publish","type":"post","link":"https:\/\/medicalmarijuanainc.com\/2022\/05\/19\/medical-marijuana-inc-reports-7-8-million-in-net-revenue-in-2022-first-quarter-financial-and-operational-results\/","title":{"rendered":"Medical Marijuana, Inc. Reports $7.8 Million in Net Revenue in 2022 First Quarter Financial and Operational Results"},"content":{"rendered":"
SAN DIEGO, CA, May 19, 2022 (GLOBE NEWSWIRE) — via\u00a0NewMediaWire\u00a0<\/a>\u00a0\u2013\u00a0Medical Marijuana, Inc.<\/a>\u00a0(OTC: MJNA) (the \u201cCompany\u201d), the first-ever publicly traded cannabis company in the United States that launched the world\u2019s first-ever cannabis-derived nutraceutical products, brands, and supply chain, announced today its financial results for the quarter ending March 31, 2022, and provided an overview of recent operational highlights.<\/p>\n First Quarter 2022 Financial and Operational Highlights<\/b><\/p>\n \u201cOur international expansion has seen significant advancement this year already and we will continue to establish first mover advantage in countries around the world. Our established markets such as Brazil and Japan continue to see explosive growth and we are leading the way in both education and medicinal research in Latin America. Our investment companies, AXIM Biotech (OTC: AXIM) and Neuropathix (OTC:NPTX), also made important progress in their research with milestones such as commercialization of breakthrough Dry Eye diagnostic tools and positive clinical data respectively. The opportunity for our family of companies has never been greater and I remain extremely optimistic about our positioning through 2022 and beyond,\u201d said Medical Marijuana, Inc. CEO Blake Schroeder.<\/p>\n About Medical Marijuana, Inc.<\/b><\/p>\n We are a company of firsts\u00ae<\/a>. Medical Marijuana, Inc. (MJNA<\/a>) is a cannabis company with three distinct business units in the non-psychoactive cannabinoid space: a global portfolio of cannabinoid-based nutraceutical brands led by\u00a0Kannaway\u00ae<\/a>\u00a0and\u00a0HempMeds\u00ae<\/a>; a pioneer in sourcing the highest-quality legal non-psychoactive cannabis products derived from industrial hemp; and a cannabinoid-based clinical research and botanical drug development sector led by its pharmaceutical investment companies and partners including\u00a0AXIM\u00ae Biotechnologies, Inc<\/a>.<\/a>\u00a0and\u00a0Neuropathix<\/a>. Medical Marijuana, Inc. was named a top CBD producer by\u00a0CNBC<\/a>. Medical Marijuana, Inc. was also the first company to receive historic import permits for CBD products from the governments of Brazil, Mexico, Argentina, and Paraguay and is a leader in the development of international markets. The company’s flagship product\u00a0Real Scientific Hemp Oil<\/a>\u00a0has been used in several successful clinical studies throughout Mexico and Brazil to understand its safety and efficacy.<\/p>\n Medical Marijuana, Inc.’s headquarters is in San Diego, California, and additional information is available at\u00a0OTCMarkets.com<\/a>\u00a0or by visiting\u00a0www.medicalmarijuanainc.com<\/a>. To see Medical Marijuana, Inc.’s corporate video,\u00a0click here<\/a>. FORWARD-LOOKING DISCLAIMER<\/b> FOOD AND DRUG ADMINISTRATION (FDA) DISCLOSURE<\/b> LEGAL DISCLOSURE<\/b> Investor Relations Contact:<\/b> <\/p>\n","protected":false},"excerpt":{"rendered":" SAN DIEGO, CA, May 19, 2022 (GLOBE NEWSWIRE) — via\u00a0NewMediaWire\u00a0\u00a0\u2013\u00a0Medical Marijuana, Inc.\u00a0(OTC: MJNA) (the \u201cCompany\u201d), the first-ever publicly traded cannabis company in the United States that launched the world\u2019s first-ever cannabis-derived nutraceutical products, brands, and supply chain, announced today its financial results for the quarter ending March 31, 2022, and provided an overview of recent […]<\/p>\n","protected":false},"author":1,"featured_media":562,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"categories":[3,2],"tags":[],"class_list":["post-561","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company-news","category-press-releases"],"yoast_head":"\n\n
\n<\/b><\/p>\n
\nThis press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and\/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Medical Marijuana, Inc. to be materially different from the statements made herein.
\n<\/b><\/p>\n
\nThese statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
\n<\/b><\/p>\n
\nMedical Marijuana, Inc. does not sell or distribute any products that are in violation of the United States Controlled Substances Act.
\nCONTACT:<\/b>
\nPublic Relations Contact:<\/b>
\nKathryn Brown
\nPR Account Director
\nCMW Media
\nP. 858-221-8001
\nkathryn@cmwmedia.com<\/a>
\nwww.cmwmedia.com<\/a><\/p>\n
\nP. (858) 283-4016
\nInvestors@medicalmarijuanainc.com<\/p>\n